Sabina Cosulich

AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with <i>In vitro</i> and <i>In vivo</i> Antitumor Activity

Christine M. Chresta, Barry R. Davies, Ian Hickson et al. · Cancer Research · 2009 · 795 citations · Full text

Medicine, Oncology, Pharmacology +13

Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor

Vanessa Rodrik-Outmezguine, Masanori Okaniwa, Zhan Yao et al. · Nature · 2016 · 482 citations

Medicine, Pharmacology, Pharmacotherapy +11

Kinase-Substrate Enrichment Analysis Provides Insights into the Heterogeneity of Signaling Pathway Activation in Leukemia Cells

Pedro Casado, Juan‐Carlos Rodríguez‐Prados, Sabina Cosulich et al. · Science Signaling · 2013 · 470 citations

Life Sciences, Cell Biology, Oncology +11

Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)

Juan Manuel García‐Martínez, Jennifer L. Moran, Rosemary G. Clarke et al. · Biochemical Journal · 2009 · 462 citations · Full text

Life Sciences, Cell Biology, Pharmacology +13

Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background

Barry R. Davies, Hannah E. Greenwood, Phillippa Dudley et al. · Molecular Cancer Therapeutics · 2012 · 461 citations · Full text

Medicine, Oncology, Pharmacology +16